Latest & greatest articles for acyclovir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acyclovir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on acyclovir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for acyclovir

1. Acyclovir

Acyclovir Top results for acyclovir - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for acyclovir The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

2018 Trip Latest and Greatest

2. Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination (PubMed)

Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination 29296807 2018 11 13 2473-9529 1 2 2016 Dec 13 Blood advances Blood Adv Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. 152-159 10.1182/bloodadvances.2016000836 Varicella zoster virus (VZV) disease (usually cutaneous zoster) occurs frequently after hematopoietic cell transplantation (HCT), and (...) postherpetic neuralgia (PHN) results in poor quality of life. The optimal prophylaxis of VZV disease/PHN has not been established. At our center, before 2008, VZV prophylaxis consisted of ∼1 year of post-HCT acyclovir/valacyclovir ("old strategy"), whereas post-2008 prophylaxis consisted of 2 years of acyclovir/valacyclovir followed by immunization using varicella vaccine ("new strategy"). We performed a retrospective study comparing the cumulative incidence of VZV disease and PHN among patients who

Full Text available with Trip Pro

2016 Blood advances

3. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. (PubMed)

Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. BACKGROUND: Herpes zoster ophthalmicus affects the eye and vision, and is caused by the reactivation of the varicella zoster virus in the distribution of the first division of the trigeminal nerve. An aggressive management of acute herpes zoster ophthalmicus with systemic antiviral medication is generally recommended as the standard first-line treatment for herpes zoster ophthalmicus (...) infections. Both acyclovir and its prodrug valacyclovir are medications that are approved for the systemic treatment of herpes zoster. Although it is known that valacyclovir has an improved bioavailability and steadier plasma concentration, it is currently unclear as to whether this leads to better treatment results and less ocular complications. OBJECTIVES: To assess the effects of valacyclovir versus acyclovir for the systemic antiviral treatment of herpes zoster ophthalmicus in immunocompetent

Full Text available with Trip Pro

2016 Cochrane

4. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial (PubMed)

Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial 26142452 2016 01 22 2016 06 09 2017 02 20 1537-6613 213 4 2016 Feb 15 The Journal of infectious diseases J. Infect. Dis. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. 551-5 10.1093/infdis/jiv318 Human immunodeficiency virus (HIV)-infected persons have higher rates of herpes (...) zoster than HIV-uninfected individuals. We assessed whether twice daily treatment with 400 mg of oral acyclovir reduces the incidence of herpes zoster in a randomized, double-blind, placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2. During 5175 person-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, compared with 69 cases among those assigned placebo (rates, 1.00 and 2.68/100 person-years, respectively), a relative

Full Text available with Trip Pro

2015 EvidenceUpdates

5. Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines

Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions In the last five years there has been very limited new evidence on the effectiveness of oral antivirals in children with chickenpox, pregnant women

2014 Health Technology Assessment (HTA) Database.

6. Idoxuridine 10% Gel Appears Equally Effective As acyclovir 5% Cream In Treating Herpes Labialis

Idoxuridine 10% Gel Appears Equally Effective As acyclovir 5% Cream In Treating Herpes Labialis UTCAT2394, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Idoxuridine 10% Gel Appears Equally Effective As acyclovir 5% Cream In Treating Herpes Labialis Clinical Question Will idoxuridine treatment have a better wound healing outcome than acyclovir in a patient with recurrent Herpes labials? Clinical Bottom Line Acyclovir (...) hours. This is the only study that has been done comparing the two drugs and full article is in French. Evidence Search ("idoxuridine"[Mesh]) AND "Acyclovir"[Mesh]) AND "Herpes labialis"[Mesh} Comments on The Evidence The sole direct comparison study of topical acyclovir against topical idoxuridine in the treatment of herpes labials is only published as a "letter to the editor" in the English language. As such it is not available for review and there is no evidence of study replication. While

2013 UTHSCSA Dental School CAT Library

7. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Suppression of subclinical sheddi... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1996 ) Volume: 124 , Issue: 1 Pt 1 , Pages: 8-15 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To assess the effect of the antiviral drug acyclovir on the frequency of subclinical shedding of herpes (...) simplex virus (HSV) in the genital tract. DESIGN: A double-blind, placebo-controlled, crossover clinical trial. SETTING: A university-based virology research clinic. PATIENTS: 34 women with herpes simplex virus type 2 (HSV-2) antibody only and genital herpes of less than 2 years' duration. INTERVENTION: Participants were randomly assigned to receive either acyclovir, 400 mg twice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the study medications

2013 Annals of Internal Medicine

8. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir [see comments]

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir [see comments] Suppression of subclinical sheddi... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1996 ) Volume: 124 , Issue: 1 Pt 1 , Pages: 8-15 Find this paper at: Abstract OBJECTIVE: To assess the effect of the antiviral drug acyclovir on the frequency of subclinical shedding of herpes simplex virus (...) (HSV) in the genital tract. DESIGN: A double-blind, placebo-controlled, crossover clinical trial. SETTING: A university-based virology research clinic. PATIENTS: 34 women with herpes simplex virus type 2 (HSV-2) antibody only and genital herpes of less than 2 years' duration. INTERVENTION: Participants were randomly assigned to receive either acyclovir, 400 mg twice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the study medications in the reverse order

2013 Annals of Internal Medicine

9. Intravenous acyclovir treatment for primary genital herpes.

Intravenous acyclovir treatment for primary genital herpes. Intravenous acyclovir treatment f... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1982 ) Volume: 98 , Issue: 6 , Pages: 914-921 PubMed: Available from or Find this paper at: Abstract Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo (...) or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p less than 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p less than or equal to 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing

2013 Annals of Internal Medicine

10. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial.

Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Intravenous acyclovir to treat mu... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1982 ) Volume: 96 , Issue: 3 , Pages: 265-269 PubMed: Available from or Find this paper at: Abstract Acyclovir, a new antiviral agent, was compared to a placebo in a randomized (...) double-blind trial of treatment for culture-proven herpes simplex virus infection after marrow transplantation. Patients received either intravenous acyclovir at 750 mg/m2 body surface area per day or a placebo for 7 days. Thirteen of 17 patients given acyclovir had a beneficial response as compared with two of 17 given the placebo (p less than 0.01). The duration of positive cultures was shorter among acyclovir recipients (3 versus 17 days, p less than 0.00005). Also shorter were the median days

2013 Annals of Internal Medicine

11. Sitavig (acyclovir ) Buccal Tablet

Sitavig (acyclovir ) Buccal Tablet Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - SITAVIG (acyclovir ) Buccal Tablet Company: BioAlliance Pharma Application No.: 203791 Approval Date: 04/12/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

12. Cohort study: Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy

Cohort study: Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy Article Text Online articles Cohort study Delayed

2013 Evidence-Based Medicine (Requires free registration)

13. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial (PubMed)

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial 21998479 2011 11 08 2012 01 18 2016 10 19 1537-6613 204 12 2011 Dec 15 The Journal of infectious diseases J. Infect. Dis. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons (...) : a randomized, crossover trial. 1912-7 10.1093/infdis/jir649 Standard-dose HSV-2 suppressive therapy (acyclovir 400 mg twice daily) reduces plasma HIV-1 levels by 0.25-0.50 log(10) copies/mL. It is not known if higher doses might further suppress HIV-1 levels. We enrolled 32 HIV-1/HSV-2 dually infected Kenyan individuals who were not on antiretroviral therapy (ART) into a randomized, crossover trial of 2 dosing regimens of HSV-2 suppression: valacyclovir 1.5 g vs acyclovir 400 mg, both twice daily for 12

Full Text available with Trip Pro

2012 EvidenceUpdates

14. Oral acyclovir suppression and neurodevelopment after neonatal herpes. (PubMed)

Oral acyclovir suppression and neurodevelopment after neonatal herpes. 21991950 2011 10 13 2011 10 24 2016 12 15 1533-4406 365 14 2011 Oct 06 The New England journal of medicine N. Engl. J. Med. Oral acyclovir suppression and neurodevelopment after neonatal herpes. 1284-92 10.1056/NEJMoa1003509 Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease. We enrolled neonates with HSV disease (...) in two parallel, identical, double-blind, placebo-controlled studies. Neonates with central nervous system (CNS) involvement were enrolled in one study, and neonates with skin, eye, and mouth involvement only were enrolled in the other. After completing a regimen of 14 to 21 days of parenteral acyclovir, the infants were randomly assigned to immediate acyclovir suppression (300 mg per square meter of body-surface area per dose orally, three times daily for 6 months) or placebo. Cutaneous recurrences

Full Text available with Trip Pro

2011 NEJM

15. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial (PubMed)

Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial 19715417 2009 09 02 2009 10 28 2013 11 21 0022-1899 200 7 2009 Oct 01 The Journal of infectious diseases J. Infect. Dis. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. 1039-49 10.1086/605647 It is uncertain whether episodic (...) acyclovir will enhance ulcer healing if delivered at primary health care settings, because there is often a delay in treatment initiation. A double-blind, randomized, placebo-controlled trial of 5-day acyclovir (400 mg 3 times daily) was conducted among men with genital ulcers in South Africa. Participants received syndromic management; were tested for ulcer etiology, human immunodeficiency virus (HIV), syphilis, and herpes simplex virus type 2 (HSV-2); and were seen over the course of a month

Full Text available with Trip Pro

2010 EvidenceUpdates

16. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. (PubMed)

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. 20153888 2010 03 08 2010 03 23 2016 12 15 1474-547X 375 9717 2010 Mar 06 Lancet (London, England) Lancet Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. 824-33 10.1016/S0140-6736(09)62038-9 Most people infected with HIV-1 are dually (...) infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of acyclovir on HIV-1 progression. In a trial with 14 sites in southern Africa and east Africa, 3381 heterosexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assigned in a 1:1 ratio to acyclovir 400 mg orally twice daily or placebo, and were followed up

Full Text available with Trip Pro

2010 Lancet

17. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. (PubMed)

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. 20089951 2010 02 04 2010 02 19 2016 12 15 1533-4406 362 5 2010 Feb 04 The New England journal of medicine N. Engl. J. Med. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. 427-39 10.1056/NEJMoa0904849 Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated (...) and is associated with increased plasma and genital levels of HIV-1. Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1. We conducted a randomized, placebo-controlled trial of suppressive therapy for HSV-2 (acyclovir at a dose of 400 mg orally twice daily) in couples in which only one of the partners was seropositive for HIV-1 (CD4 count, > or = 250 cells per cubic millimeter

Full Text available with Trip Pro

2010 NEJM

18. Treatment with acyclovir five times daily may reduce the duration of primary herpetic oral lesions

Treatment with acyclovir five times daily may reduce the duration of primary herpetic oral lesions UTCAT491, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Treatment with acyclovir five times daily may reduce the duration of primary herpetic oral lesions Clinical Question In children experiencing primary herpetic gingivostomatitis, does treatment with acyclovir, compared to no treatment, reduce the duration of oral (...) lesions? Clinical Bottom Line Treatment with acyclovir 5 times daily could reduce the duration of primary herpetic oral lesions. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Nasser/2008 Children and young adults Systematic review Key results Two randomized controlled trials were included in this systematic review. One provided weak evidence that acyclovir is an effective

2010 UTHSCSA Dental School CAT Library

19. Acyclovir for treating primary herpetic gingivostomatitis. (PubMed)

Acyclovir for treating primary herpetic gingivostomatitis. BACKGROUND: Primary herpetic gingivostomatitis is a highly contagious infection of the oral cavity which typically affects children but can also occur in adults. Symptoms may vary widely from mild discomfort to life-threatening encephalitis. OBJECTIVES: The objective of this review was to evaluate the effectiveness of systemic acyclovir for primary herpetic gingivostomatitis. SEARCH STRATEGY: We searched the following databases (...) : Cochrane Oral Health Group's Trials Register (to 22 May 2008); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 2); MEDLINE (1950 to 22 May 2008); and EMBASE (1980 to 22 May 2008). There were no language restrictions. SELECTION CRITERIA: Randomised controlled trials comparing acyclovir to placebo in children and young adults < 25 years of age with a diagnosis of primary herpetic gingivostomatitis with or without herpes labialis were considered. DATA

Full Text available with Trip Pro

2008 Cochrane

20. Some evidence that acyclovir is effective for treating primary herpetic gingivostomatitis

Some evidence that acyclovir is effective for treating primary herpetic gingivostomatitis PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Some evidence that acyclovir is effective for treating primary herpetic gingivostomatitis Clinical question How effective is acyclovir for treating primary herpetic gingivostomatitis (PHG)? Bottom line One trial (n=72) provided some limited evidence (...) to suggest for children under 6 years of age with PHG acyclovir is effective in reducing the number of oral lesions (NNT* 2), preventing the development of new extraoral lesions (NNT 3), decreasing the difficulty experienced in eating (NNT 3) and drinking (NNT 5) and reducing admissions to hospital (NNT 12). * NNT = number needed to treat to benefit 1 individual. Caveat Only 2 trials, one with 72 participants and the other with 20 participants, were included in this review. The second study failed

2008 Cochrane PEARLS